From the Departments of Medicine (M.C.F., A.S.G.) and Epidemiology & Biostatistics (A.S.G.), University of California, San Francisco; Division of Research (A.S.G., N.K.P., N.U.), Kaiser Permanente of Northern California, Oakland; and Clinical Epidemiology Unit (Y.C., L.H.B., D.E.S.), General Medicine Division, Massachusetts General Hospital, Boston.
Neurology. 2014 Mar 25;82(12):1033-7. doi: 10.1212/WNL.0000000000000248. Epub 2014 Feb 14.
While the short-term impact of atrial fibrillation-related stroke has been well studied, surprisingly little is known about its long-term effect on survival.
We followed 13,559 patients with atrial fibrillation for a median of 6 years, identifying ischemic strokes through computerized databases and validating 1,025 events. Stroke severity was determined from hospital records. We compared survival of stroke patients with comparator nonstroke patients (matched for age, sex, race, comorbid conditions, and time of entry into the cohort) using proportional hazard models controlling for warfarin use and compared survival by degree of discharge deficit.
Median survival after stroke was 1.8 years compared with 5.7 years for matched nonstroke comparators (hazard ratio [HR] 2.8, 95% confidence interval [CI] 2.5-3.2). This increased risk of all-cause death persisted even after restricting the analysis to the 576 stroke patients who survived 6 months after the initial stroke event (HR 2.0, 95% CI 1.7-2.5, adjusting for warfarin use). Risk of death was strongly associated with stroke severity: HR 2.9 (95% CI 2.3-3.5) for strokes resulting in major deficits and HR 8.3 (95% CI 5.2-13.2) for strokes resulting in severe deficits compared with matched comparators without stroke.
Ischemic stroke approximately triples the mortality rate in patients with atrial fibrillation. This effect persists well beyond the immediate period poststroke and is strongly associated with disability after stroke. Stroke prevention by anticoagulation has even greater beneficial effects on survival than usually considered when focusing solely on 30-day mortality rates.
尽管已经充分研究了房颤相关性卒中的短期影响,但对于其对生存的长期影响却知之甚少。
我们对 13559 例房颤患者进行了中位时间为 6 年的随访,通过计算机数据库确定了缺血性卒中,并验证了 1025 例事件。根据住院记录确定卒中严重程度。我们使用比例风险模型比较了卒中患者和对照组非卒中患者(按年龄、性别、种族、合并症和进入队列时间匹配)的生存情况,并根据出院时的功能缺损程度比较了生存情况。
卒中后中位生存时间为 1.8 年,而匹配的非卒中对照组为 5.7 年(风险比[HR]2.8,95%置信区间[CI]2.5-3.2)。即使在将分析仅限于 576 例初始卒中事件后存活 6 个月的卒中患者时,这种全因死亡风险增加仍然存在(HR 2.0,95%CI 1.7-2.5,调整华法林的使用)。死亡风险与卒中严重程度密切相关:与无卒中的匹配对照组相比,导致严重功能缺损的卒中患者的 HR 为 2.9(95%CI 2.3-3.5),而导致严重功能缺损的卒中患者的 HR 为 8.3(95%CI 5.2-13.2)。
缺血性卒中使房颤患者的死亡率增加约两倍。这种影响持续时间远超过卒中后的即刻时期,并且与卒中后的残疾密切相关。通过抗凝预防卒中对生存的有益影响甚至比仅关注 30 天死亡率时所认为的更大。